Author Archives: Joana Carvalho

1st Relapsing MS Patient Enrolls in Phase 3 Trial of Oral SAR442168

A first person has enrolled in Sanofi’s Phase 3 trial evaluating SAR442168, an oral BTK inhibitor intended to treat relapsing forms of multiple sclerosis (MS), Sanofi’s partner, Principia Biopharma, announced. “We are delighted that Sanofi has initiated … [this] trial in patients with relapsing MS,” Roy Hardiman, chief…

Gilenya May Help Control Severe Respiratory Disease in COVID-19

Gilenya (fingolimod), which works to modulate immune system activity in multiple sclerosis (MS), may benefit people with severe respiratory disease associated with COVID-19, a case report highlights. The study, “Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod,” was published in…

MMJ Can Ship Cannabis Products to US for Clinical Testing, Agencies Say

MMJ International Holdings announced that it has been given clearance to ship its cannabis-based products to the U.S. for use in future clinical trials of potential cannabis-based treatment for multiple sclerosis (MS) and Huntington’s disease. The process was facilitated by the U.S. Drug Enforcement Agency (DEA), which worked alongside…

Mix of Broad and Specific Language May Help in Talking About MS

Using a mix of broad diagnostic terms and more disease-specific ones may help physicians and patients to better communicate symptoms of autoimmune disorders like multiple sclerosis (MS) that are not always obvious or easy to explain, a study reported. The study, “Using autoimmune strategically: Diagnostic lumping, splitting,…

Myelin Health Depends on Steady Supply of Lipids, Study Suggests

Continuous production of fatty molecules (lipids) is crucial to the maintenance of the myelin sheath that wraps nerve fibers to protect them, ensuring the transmission of electrical impulses between nerve cells, a study reported. These findings may have strong implications for treating disorders caused by myelin loss, including…

Tysabri May Promote Inflammatory B-Cell Activation in MS Patients, Study Says

Tysabri (natalizumab), an effective T-cell targeting treatment for multiple sclerosis (MS), seems to also promote the activation of pro-inflammatory immune B-cells in people with this disease, a study found. The study, “Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients,” was published in the…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Video